High Residual Platelet Reactivity during Aspirin Therapy in Patients with Non-St Segment Elevation Acute Coronary Syndrome: Comparison Between Initial and Late Phases

Abstract Background: High platelet reactivity (HPR) during therapy with acetylsalicylic acid (ASA) is a poor prognostic factor in acute coronary syndromes (ACS). The prevalence of HPR during ACS is greater than that reported in stable diseases. However, it is unclear whether this prevalence of HPR is a transient phenomenon or a characteristic of this high-risk population. Objective: The main objective is to compare the effects of ASA on platelet function in the initial and late phases of ACS in a single population. Secondary objectives are: correlation between the tests between themselves and the relationship between the tests and the variation of the inflammatory markers (C-reactive protein and interleukin-6). Methods: Seventy patients with non-ST segment elevation (NSTE) ACS in use of 100-200 mg of ASA per day for at least 7 days were prospectively studied. Platelet function was assessed in the first 48 hours and subsequently after 3 months using four methods: VerifyNow™ (VFN), whole blood platelet aggregation (WBPA) with arachidonic acid (AA) and collagen as agonists, and platelet function analyzer (PFA). The level of statistical significance considered was < 0.05. Results: According to the more specific methods (WBPA with AA and VFN), the incidence of HPR was significantly higher in the early phase than in the late phase: WBPA with AA: 31% versus 13%, p = 0.015; VFN: 32% versus 16%, p = 0.049. The other methods tested, which were less specific for ASA, did not show significant differences between phases. The correlation between the methods was weak or moderate (r ranging from 0.3 to 0.5, p < 0.05), and there were no significant associations between HPR and inflammatory markers. Conclusion: The prevalence of HPR during AAS therapy, assessed by specific methods for cyclooxygenase 1 (COX-1), is higher during the acute phase than in the late phase of NSTE ACS.

Saved in:
Bibliographic Details
Main Authors: Dracoulakis,Marianna Deway Andrade, Gurbel,Paul, Cattaneo,Marco, Martins,Herlon Saraiva, Nicolau,José Carlos, Kalil Filho,Roberto
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Cardiologia - SBC 2019
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2019000900357
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0066-782X2019000900357
record_format ojs
spelling oai:scielo:S0066-782X20190009003572019-10-08High Residual Platelet Reactivity during Aspirin Therapy in Patients with Non-St Segment Elevation Acute Coronary Syndrome: Comparison Between Initial and Late PhasesDracoulakis,Marianna Deway AndradeGurbel,PaulCattaneo,MarcoMartins,Herlon SaraivaNicolau,José CarlosKalil Filho,Roberto Acute Coronary Syndrome Platelet Aggregation/drug effects Myocardial Ischemia Aged aspirin/therapeutic use Aspirin/adverse effects Abstract Background: High platelet reactivity (HPR) during therapy with acetylsalicylic acid (ASA) is a poor prognostic factor in acute coronary syndromes (ACS). The prevalence of HPR during ACS is greater than that reported in stable diseases. However, it is unclear whether this prevalence of HPR is a transient phenomenon or a characteristic of this high-risk population. Objective: The main objective is to compare the effects of ASA on platelet function in the initial and late phases of ACS in a single population. Secondary objectives are: correlation between the tests between themselves and the relationship between the tests and the variation of the inflammatory markers (C-reactive protein and interleukin-6). Methods: Seventy patients with non-ST segment elevation (NSTE) ACS in use of 100-200 mg of ASA per day for at least 7 days were prospectively studied. Platelet function was assessed in the first 48 hours and subsequently after 3 months using four methods: VerifyNow™ (VFN), whole blood platelet aggregation (WBPA) with arachidonic acid (AA) and collagen as agonists, and platelet function analyzer (PFA). The level of statistical significance considered was < 0.05. Results: According to the more specific methods (WBPA with AA and VFN), the incidence of HPR was significantly higher in the early phase than in the late phase: WBPA with AA: 31% versus 13%, p = 0.015; VFN: 32% versus 16%, p = 0.049. The other methods tested, which were less specific for ASA, did not show significant differences between phases. The correlation between the methods was weak or moderate (r ranging from 0.3 to 0.5, p < 0.05), and there were no significant associations between HPR and inflammatory markers. Conclusion: The prevalence of HPR during AAS therapy, assessed by specific methods for cyclooxygenase 1 (COX-1), is higher during the acute phase than in the late phase of NSTE ACS.info:eu-repo/semantics/openAccessSociedade Brasileira de Cardiologia - SBCArquivos Brasileiros de Cardiologia v.113 n.3 20192019-09-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2019000900357en10.5935/abc.20190146
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Dracoulakis,Marianna Deway Andrade
Gurbel,Paul
Cattaneo,Marco
Martins,Herlon Saraiva
Nicolau,José Carlos
Kalil Filho,Roberto
spellingShingle Dracoulakis,Marianna Deway Andrade
Gurbel,Paul
Cattaneo,Marco
Martins,Herlon Saraiva
Nicolau,José Carlos
Kalil Filho,Roberto
High Residual Platelet Reactivity during Aspirin Therapy in Patients with Non-St Segment Elevation Acute Coronary Syndrome: Comparison Between Initial and Late Phases
author_facet Dracoulakis,Marianna Deway Andrade
Gurbel,Paul
Cattaneo,Marco
Martins,Herlon Saraiva
Nicolau,José Carlos
Kalil Filho,Roberto
author_sort Dracoulakis,Marianna Deway Andrade
title High Residual Platelet Reactivity during Aspirin Therapy in Patients with Non-St Segment Elevation Acute Coronary Syndrome: Comparison Between Initial and Late Phases
title_short High Residual Platelet Reactivity during Aspirin Therapy in Patients with Non-St Segment Elevation Acute Coronary Syndrome: Comparison Between Initial and Late Phases
title_full High Residual Platelet Reactivity during Aspirin Therapy in Patients with Non-St Segment Elevation Acute Coronary Syndrome: Comparison Between Initial and Late Phases
title_fullStr High Residual Platelet Reactivity during Aspirin Therapy in Patients with Non-St Segment Elevation Acute Coronary Syndrome: Comparison Between Initial and Late Phases
title_full_unstemmed High Residual Platelet Reactivity during Aspirin Therapy in Patients with Non-St Segment Elevation Acute Coronary Syndrome: Comparison Between Initial and Late Phases
title_sort high residual platelet reactivity during aspirin therapy in patients with non-st segment elevation acute coronary syndrome: comparison between initial and late phases
description Abstract Background: High platelet reactivity (HPR) during therapy with acetylsalicylic acid (ASA) is a poor prognostic factor in acute coronary syndromes (ACS). The prevalence of HPR during ACS is greater than that reported in stable diseases. However, it is unclear whether this prevalence of HPR is a transient phenomenon or a characteristic of this high-risk population. Objective: The main objective is to compare the effects of ASA on platelet function in the initial and late phases of ACS in a single population. Secondary objectives are: correlation between the tests between themselves and the relationship between the tests and the variation of the inflammatory markers (C-reactive protein and interleukin-6). Methods: Seventy patients with non-ST segment elevation (NSTE) ACS in use of 100-200 mg of ASA per day for at least 7 days were prospectively studied. Platelet function was assessed in the first 48 hours and subsequently after 3 months using four methods: VerifyNow™ (VFN), whole blood platelet aggregation (WBPA) with arachidonic acid (AA) and collagen as agonists, and platelet function analyzer (PFA). The level of statistical significance considered was < 0.05. Results: According to the more specific methods (WBPA with AA and VFN), the incidence of HPR was significantly higher in the early phase than in the late phase: WBPA with AA: 31% versus 13%, p = 0.015; VFN: 32% versus 16%, p = 0.049. The other methods tested, which were less specific for ASA, did not show significant differences between phases. The correlation between the methods was weak or moderate (r ranging from 0.3 to 0.5, p < 0.05), and there were no significant associations between HPR and inflammatory markers. Conclusion: The prevalence of HPR during AAS therapy, assessed by specific methods for cyclooxygenase 1 (COX-1), is higher during the acute phase than in the late phase of NSTE ACS.
publisher Sociedade Brasileira de Cardiologia - SBC
publishDate 2019
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2019000900357
work_keys_str_mv AT dracoulakismariannadewayandrade highresidualplateletreactivityduringaspirintherapyinpatientswithnonstsegmentelevationacutecoronarysyndromecomparisonbetweeninitialandlatephases
AT gurbelpaul highresidualplateletreactivityduringaspirintherapyinpatientswithnonstsegmentelevationacutecoronarysyndromecomparisonbetweeninitialandlatephases
AT cattaneomarco highresidualplateletreactivityduringaspirintherapyinpatientswithnonstsegmentelevationacutecoronarysyndromecomparisonbetweeninitialandlatephases
AT martinsherlonsaraiva highresidualplateletreactivityduringaspirintherapyinpatientswithnonstsegmentelevationacutecoronarysyndromecomparisonbetweeninitialandlatephases
AT nicolaujosecarlos highresidualplateletreactivityduringaspirintherapyinpatientswithnonstsegmentelevationacutecoronarysyndromecomparisonbetweeninitialandlatephases
AT kalilfilhoroberto highresidualplateletreactivityduringaspirintherapyinpatientswithnonstsegmentelevationacutecoronarysyndromecomparisonbetweeninitialandlatephases
_version_ 1756382152672411648